Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Shionogi"


8 mentions found


Goldman Sachs has refreshed its conviction list of top stocks in Asia Pacific this month, adding some names and removing others. Here are two additions to Goldman Sachs' Asian conviction list, and two removals: China Resources Beer Goldman analyst Leaf Liu said he was positive on the outlook for Chinese beer manufacturer and distributor China Resources Beer . Goldman Sachs has a 12-month price target of 51 Hong Kong dollars ($6.51) on the stock, giving it potential upside of around 46%. NTPC India's power generation company NTPC — formerly the National Thermal Power Corporation — was another addition to Goldman's conviction list. Shionogi, China Medical System Meanwhile, the Wall Street bank removed two pharmaceutical players — Japan's Shionogi and the China-headquartered China Medical System — from its conviction list.
Persons: Goldman Sachs, China Resources Beer, Leaf Liu, CRB, , National Thermal Power Corporation —, Apoorva Bahadur, Bahadur, Goldman, — Japan's Shionogi, — CNBC's Michael Bloom Organizations: MSCI Asia, China Resources, China Resources Beer Goldman, China Resources Beer, Brands, Star, Heineken, Hong, Franklin FTSE, National Thermal Power Corporation Locations: Asia Pacific, Japan, China, ,, Tianjin, premiumization, Hong Kong, Franklin FTSE China, Shionogi
March 30 (Reuters) - A federal judge in Texas on Thursday blocked Obamacare's mandate that health insurance plans cover pre-exposure prophylaxis against HIV (PrEP) and other preventive care including cancer and diabetes screenings. U.S. District Judge Reed O'Connor in Fort Worth, Texas, said the PrEP mandate violated a federal religious freedom law and that the other preventive care mandates were based on recommendations by an illegally appointed task force. The ruling was a victory for conservative businesses and individuals that sued to challenge the mandates in 2020. The U.S. Department of Health and Human Services, which oversees Obamacare, did not immediately respond to a request for comment. Reporting By Brendan Pierson in New York; Editing by Mark PorterOur Standards: The Thomson Reuters Trust Principles.
Xocova, a protease inhibitor like the COVID treatments developed by Pfizer Inc (PFE.N) and Merck & Co (MRK.N), was granted emergency approval by Japanese regulators in November, making it the nation's first domestically produced oral treatment for COVID. "If you kill the virus fast enough and sharp enough, the lower the probability of long COVID. According to one study by the Veterans Affairs St. Louis Health Care System, Pfizer's antiviral drug Paxlovid cuts the risk of developing many long COVID symptoms. Shionogi is hoping for Xocova sales of around $1 billion to $1.5 billion this year. "I have no regrets," Teshirogi said, adding that expectations among shareholders and the public had demanded that Shionogi devote its resources to fighting COVID.
U.S. NIH starts trial for Shionogi's COVID-19 pill
  + stars: | 2023-02-15 | by ( ) www.reuters.com   time to read: 1 min
Feb 15 (Reuters) - The U.S. National Institutes of Health (NIH) said on Wednesday that it had started a clinical trial to evaluate Japan's Shionogi & Co Ltd's (4507.T) experimental oral antiviral drug to treat COVID-19. The drug, S-217622 or ensitrelvir, will be tested in adult patients hospitalized with COVID-19. Ensitrelvir is an oral antiviral agent taken once daily for five days to suppress replication of the virus. The trial will enroll about 1,500 people from different sites across the world, the government health organization said in a statement. Reporting by Mariam E Sunny; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.
He heard at that time that Pfizer's (PFE.N) anti-viral drug Paxlovid was an effective treatment, but patients could only get it prescribed if they were admitted to hospital, and only if the drug was in stock. Li's experience, local media reports and online posts bear testimony to the difficulties faced obtaining Paxlovid in China through official channels. "Pfizer is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China. We remain committed to fulfilling the COVID-19 treatment needs of Chinese patients and partnering with the Chinese government," the company said in a statement. PAXLOVID GIFTSeveral other people described to Reuters how they turned to the grey market to purchase Paxlovid.
Japan Approves First Homegrown Covid-19 Antiviral Pill
  + stars: | 2022-11-22 | by ( Megumi Fujikawa | ) www.wsj.com   time to read: 1 min
TOKYO—Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug’s efficacy. The treatment is the first locally developed alternative to Pfizer Inc.’s Paxlovid and Merck & Co.’s Lagevrio, which have been authorized for emergency use in Japan. Shionogi aims to win approval from the Food and Drug Administration for its pill in the U.S.
Regulators in Japan previously denied emergency approval for the Shionogi pill, saying they wanted to see more data on its effectiveness. There were also concerns the drug could pose risk to pregnancies, based on results from animal studies. If approved, it would become the first domestically developed oral drug for COVID patients with mild symptoms. Despite the delay in approving the treatment, Shionogi last month raised its full-year sales forecast on expectations it would win regulatory approval. The company has signed an agreement to sell about a million doses to the government, pending the drug's approval.
Shionogi says COVID pill trial shows reduction in symptoms
  + stars: | 2022-09-28 | by ( ) www.reuters.com   time to read: +2 min
TOKYO, Sept 28 (Reuters) - Japan's Shionogi & Co Ltd (4507.T) said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia. Regulatory authorities in Japan previously denied emergency approval for use of the pill, saying they wanted to see more data on its effectiveness. read moreShionogi said it has shared top-line data from the Phase III study with Japanese regulators as part of deliberations on approval of the drug. The company has signed an agreement to sell about a million doses to the government, pending the drug's approval. The firm has received U.S. government support for a global Phase III trial.
Total: 8